

MTN 035 - Rectal Microbicide Acceptability, Tolerability, and Adherence
Report Generation Date: December 2, 2025
Data as of: December 2, 2020¹
Retention by Visit and Site(Interim Visits Included)

	Birmingham	Blantyre	Chiang Mai	Hillbrow, WRHI	Lima, San Miguel	Pittsburgh	San Francisco	All Sites
Participants Enrolled	33	31	30	30	30	33	30	217
Visit 3: Day 28/Week 4 - 1st PUEV								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	30 (91%)	30 (97%)	30 (100%)	28 (93%)	28 (97%)	30 (91%)	30 (100%)	206 (95%)
Not Completed	3 (9%)	1 (3%)	0 (0%)	2 (7%)	1 (3%)	3 (9%)	0 (0%)	10 (5%)
Missed	3 (9%)	0 (0%)	0 (0%)	2 (7%)	1 (3%)	3 (9%)	0 (0%)	9 (4%)
Terminated Early	0 (0%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)
Not Expected	0	0	0	0	0	0	0	0
Visit 4: Day 35/Week 5 - Product Switch Visit								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	30 (91%)	30 (97%)	30 (100%)	28 (93%)	29 (100%)	31 (94%)	30 (100%)	208 (96%)
Not Completed	3 (9%)	1 (3%)	0 (0%)	2 (7%)	0 (0%)	2 (6%)	0 (0%)	8 (4%)
Missed	1 (3%)	0 (0%)	0 (0%)	2 (7%)	0 (0%)	2 (6%)	0 (0%)	5 (2%)
Terminated Early	2 (6%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (1%)
Not Expected	0	0	0	0	0	0	0	0
Visit 5: Day 63/Week 9 - 2nd PUEV								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	29 (88%)	30 (97%)	29 (97%)	27 (90%)	26 (90%)	30 (91%)	29 (97%)	200 (93%)
Not Completed	4 (12%)	1 (3%)	1 (3%)	3 (10%)	3 (10%)	3 (9%)	1 (3%)	16 (7%)
Missed	1 (3%)	0 (0%)	1 (3%)	3 (10%)	3 (10%)	0 (0%)	1 (3%)	9 (4%)
Terminated Early	3 (9%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	3 (9%)	0 (0%)	7 (3%)
Not Expected	0	0	0	0	0	0	0	0
Visit 6: Day 70/Week 10 - Product Switch Visit								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	29 (88%)	30 (97%)	30 (100%)	28 (93%)	26 (90%)	30 (91%)	30 (100%)	203 (94%)
Not Completed	4 (12%)	1 (3%)	0 (0%)	2 (7%)	3 (10%)	3 (9%)	0 (0%)	13 (6%)
Missed	1 (3%)	0 (0%)	0 (0%)	2 (7%)	3 (10%)	0 (0%)	0 (0%)	6 (3%)
Terminated Early	3 (9%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	3 (9%)	0 (0%)	7 (3%)
Not Expected	0	0	0	0	0	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form or the Interim visit summary form for make-up visit is received at SCHARP.

MTN 035 - Rectal Microbicide Acceptability, Tolerability, and Adherence

Report Generation Date: December 2, 2025

Data as of: December 2, 2020¹

Retention by Visit and Site(Interim Visits Included)

	Birmingham	Blantyre	Chiang Mai	Hillbrow, WRHI	Lima,San Miguel	Pittsburgh	San Francisco	All Sites
Visit 7: Day 98/Week 14 - 3rd PUEV								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	29 (88%)	29 (94%)	30 (100%)	26 (87%)	25 (86%)	30 (91%)	30 (100%)	199 (92%)
Not Completed	4 (12%)	2 (6%)	0 (0%)	4 (13%)	4 (14%)	3 (9%)	0 (0%)	17 (8%)
Missed	0 (0%)	1 (3%)	0 (0%)	4 (13%)	3 (10%)	0 (0%)	0 (0%)	8 (4%)
Terminated Early	4 (12%)	1 (3%)	0 (0%)	0 (0%)	1 (3%)	3 (9%)	0 (0%)	9 (4%)
Not Expected	0	0	0	0	0	0	0	0
Visit 8: Day 105/Week 15 - Final Termination Visit								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	29 (88%)	26 (84%)	30 (100%)	29 (97%)	25 (86%)	30 (91%)	30 (100%)	199 (92%)
Not Completed	4 (12%)	5 (16%)	0 (0%)	1 (3%)	4 (14%)	3 (9%)	0 (0%)	17 (8%)
Missed	0 (0%)	4 (13%)	0 (0%)	0 (0%)	3 (10%)	0 (0%)	0 (0%)	7 (3%)
Terminated Early	4 (12%)	1 (3%)	0 (0%)	0 (0%)	1 (3%)	3 (9%)	0 (0%)	9 (4%)
Not Expected	0	0	0	0	0	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form or the Interim visit summary form for make-up visit is received at SCHARP.